BioCentury
ARTICLE | Company News

BeiGene to helm Asian development of Zymeworks’ HER2 antibodies

November 30, 2018 7:05 PM UTC

Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) granted BeiGene Ltd. (HKSE:6160; NASDAQ:BGNE) rights to HER2 antibodies ZW25 and ZW49, which Zymeworks said is part of its strategy to speed development by partnering assets in specific geographies.

Zymeworks said that the collaboration is expected to accelerate patient recruitment and shorten development timelines, particularly in gastroesophageal cancers, which have a higher incidence in Asian populations. The company will use data from the collaboration to support global regulatory filings in HER2 expressing solid tumors, including gastric and breast cancer...